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Respiratory bronchiolitisAbstract The aim of the study is to delineate the relation between cigarette smoking and the
development of interstitial lung disease with declaration of the different types of the interstitial lung
associated with smoking.
HRCT was done on 40 smokers. All patients had thorough clinical assessment. Blood gases were
estimated in all patients. Pulmonary function tests were done to all subjects, BAL was done in
27 patients, and trans-bronchial biopsy was done in 14 patients. None of the patients agreed to
do any surgical biopsies.
In 25 patients (n= 25, 62.5%) the HRCT ﬁndings suggested RB-ILD. Five patients (n= 5,
12.5%), were diagnosed as early DIP. Three patients (n= 3, 7.5%) showed advanced DIP. In
six patients (n= 6, 15%) the ﬁndings suggests UIP and one patient (30 year-old) had ﬁndings
suggesting PLCH.
In the appropriate clinical context high-resolution CT plays an integral role in the evaluation of
SR-ILD, the presence of typical changes at high-resolution CT renders the diagnosis almost certain
and may obviate further testing. Lung biopsy may be needed when the ﬁndings at high-resolution
CT are relatively nonspeciﬁc or when a conﬁdent deﬁnitive diagnosis is needed.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.terstitial
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1.1. Patients
Forty smokers were included in this study (all males, age range
32–82 years, mean age 54 years ± 8).
Inclusion criteria: Smokers with progressive dyspnea, where
HRCT was done and suggested interstitial disease.
1.2. Methods
1.2.1. Technique
HRCT was done to all subjects using GE Light Speed Multi-
slice 4 channels (the protocol used for examination is shown
in Table 1).
1.2.2. Interpretation
The HRCT scans of all subjects were independently assessed
by two radiologists, in a blind manner and the overall ﬁndings
were determined, recorded, and compared.
1.2.3. Other assessment methods
All patients had thorough clinical assessment. Blood gases
were estimated in all patients. Pulmonary function tests were
done to all subjects, BAL was done in 27 patients, and trans-
bronchial biopsy was done in 14 patients. None of the patients
agreed to do any surgical biopsies.
2. Introduction
Smoking-induced lung diseases constitute a complex group of
disorders, varying from the well-known entity of chronic
obstructive pulmonary disease (COPD) to the more recently
described interstitial lung diseases (ILDs) (1,2). Development
of interstitial lung disease is a recognized risk factor for ciga-
rette smoking (3).
Four interstitial lung diseases (ILDs) have been related to
cigarette smoking: respiratory bronchiolitis (RB)-associated
ILD (RB-ILD), desquamative interstitial pneumonia (DIP),
interstitial pulmonary ﬁbrosis (IPF) and pulmonary Langer-
hans cell histiocytosis (PLCH), (4).
Among patients with these disorders there is a prevalence of
current or ex-smokers: over 90% in RB-ILD, 60–90% in DIP
and 41–83% in IPF. Thus, cigarette smoking is to be a risk fac-
tor of great signiﬁcance. The combination of lower lung ﬁbro-
sis and upper lung emphysema is being increasingly recognized
as a distinct clinical entity in smokers (5).Table 1 Protocol used for HRCT examination.
Preparation: None needed.
IV contrast: None needed.
CT scanning: CT scan examinations were performed using GE Light Spe
examination is done in supine position. A scout is taken with kV 120 an
minimize respiration artifacts, using detector row 4, helical thickness 1.25,
collimation 5.00 mm, interval 1.00, gantry tilt 0.0, FOV depends on the pa
exposure time about 16 s during breath hold in inspiration.
The images and reconstruction technique: images acquired are then sent
reconstructed. Reconstruction of the images is done using reconstruction
and sagittal images. Also mediastinal window images are done for eachIn some smokers, combinations of various patterns of in-
jury can be identiﬁed in the same individual. In clinical practice
a correct differential diagnosis between RB-ILD and DIP on
one hand and IPF on the other one is very important (6).
The overlap is most signiﬁcant between RB-ILD and DIP.
Macrophage accumulation is bronchiolocentric in RB-ILD,
producing centrilobular ground-glass opacity, and more dif-
fuse in DIP, producing widespread ground-glass changes.
The coexistence of upper lung nodules and cysts in a smoker
allows conﬁdent diagnosis of PLCH (6).
There is growing evidence that in all these diseases the pri-
mary target appears to be the terminal and/or respiratory
bronchioles (4).
Respiratory bronchiolitis (RB) was ﬁrst described by
Niewhoehner et al. (8) as a discrete histopathologic entity occur-
ring in young smokers. This disorder, also called ‘‘smoker’s
bronchiolitis,’’ is characterized by the accumulation of cytoplas-
mic golden brown-pigmented macrophages within respiratory
bronchioles (9). Importantly, RB may persist in some patients
for many years after stopping smoking. (10) Furthermore, the
presence of areas of RB or DIP-like reaction can be considered
as a sensitive histologic marker of cigarette smoking.
However, a small proportion of smokers acquire a more
exaggerated response that, in addition to the respiratory bron-
chiole-centered lesions, provokes interstitial and airspace
inﬂammation and ﬁbrosis extending to the nearby alveoli. This
entity is what we called RB-ILD, and contrasting with what
occurs in the ‘‘pure’’ RB.
The most common high-resolution CT ﬁndings in RB-ILD
are centrilobular nodules, ground-glass opacities, and thicken-
ing of the bronchial walls, which predominate in the upper
lobes. Upper lobe emphysema is also commonly present. A
small percentage of patients have a reticular pattern due to
ﬁbrosis in the absence of honeycombing and traction bronchi-
ectasis (11,2). The differential diagnosis of RB-ILD includes
acute hypersensitivity pneumonitis, DIP, and nonspeciﬁc inter-
stitial pneumonitis (NSIP) (6).
Desquamative interstitial pneumonia (DIP) was initially de-
scribed by Liebow et al. (12), This disease is characterized by
the widespread accumulation of intra-alveolar macrophages,
with usually mild interstitial reaction, although some condi-
tions may evolve to ﬁbrosis and end-stage lung disease.
Currently, it is well known that the histopathologic patterns
of RB-ILD and DIP may overlap, and the key feature to dif-
ferentiate both disorders is the distribution and extent of the
lesions: bronchiolocentric in the RB-ILD, or diffuse in the
DIP (4).ed Multislice 4 channels present our radiology department. The
d mA 120,then helical scanning is done in caudo-cranial direction to
pitch 1.5:1, speed (mm/rot) 7.5, Detector conﬁguration 4 · 1.25, beam
tients’ body build, but is about 35 cm, kV 120–140, mA 120–160, total
to a separate workstation to be processed, manipulated and
software available at the workstation to attain HRCT axial, coronal
case.
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lar phase and UIP the later, ﬁbrotic phase of the same disease
(19,20) but they are now accepted as separate clinical-patho-
logic entities. The term ‘‘desquamative interstitial pneumonia’’
is a morphologic description but is a misnomer because the
dominant histologic feature is intra-alveolar macrophage accu-
mulation rather than desquamated pneumocytes.
The predominant abnormality at high-resolution CT in pa-
tients with DIP is ground-glass opacity, which may be periph-
eral, patchy, or diffuse in distribution (2,14). A peripheral
subpleural and basal predominance of ground-glass opacity
is most commonly seen. Honeycombing is uncommon. Coexis-
tent emphysema may be present. At follow-up high-resolution
CT of patients receiving treatment, the ground-glass opacity
may show partial or complete resolution (15,16). Small cystic
spaces may develop within the areas of ground-glass opacity,
although progression to reticular abnormality and honeycom-
bing is unusual. The differential diagnosis includes RB-ILD,
hypersensitivity pneumonitis, NSIP, and atypical infections
such as Pneumocystis carinii pneumonia.
The term Langerhans cell histiocytosis refers to a group of
diseases of unknown etiology often recognized in childhood,
in which Langerhans cell accumulations involve one or more
body systems, including bone, lung, pituitary gland, mucous
membranes, skin, lymph nodes, and liver. This disease is also
referred to as histiocytosis X or eosinophilic granuloma. The
term pulmonary Langerhans cell histiocytosis refers to disease
in adults that affects the lung, usually in isolation and less
commonly in addition to other organ systems (17).
The condition is uncommon, with a prevalence of 3.4% in a
series of 502 patients undergoing surgical lung biopsy for
chronic diffuse inﬁltrative lung disease (18). The peak occur-
rence is at 20–40 years of age.
The clinical presentation of PLCH varies; dyspnea, cough,
and chest pain are predominant symptoms. Approximately
25% of patients are asymptomatic, and the disease is uncov-
ered on a routine chest radiograph. Constitutional symptoms
(fever, fatigue, night sweats, anorexia, and weight loss) and
hemoptysis can occur (19,20). In 10% of cases, PLCH presents
with spontaneous pneumothorax, which can be bilateral or
recurrent (21).
In patients with PLCH, typical ﬁndings on chest radio-
graphs include nodular or reticulonodular opacities most
prominent in the middle and upper lung zones (19). There is
usually sparing of the costophrenic angles and the lung volume
appears normal or increased.
High-resolution CT is sensitive and speciﬁc for the diagno-
sis of PLCH, the characteristic ﬁnding being a combination of
nodules and cysts predominating in the upper and mid lungs,
sparing the bases. Early in the disease, nodules with irregular
borders predominate, mainly in a peribronchiolar distribution.
As the disease evolves, thick- or thin-walled cysts predominate
and are often irregular. Longitudinal studies with high-resolu-
tion CT show that the solid nodules progress to cavitary nod-
ules, then thick-walled cysts, and ﬁnally thin-walled cysts (13).
A relationship between cigarette smoking and Interstitial
Pulmonary Fibrosis has been recognized for many years (6).
IPF, is also called cryptogenic ﬁbrosing alveolitis in Europe
(23).
Alveolar wall ﬁbrosis in addition to coexistent emphysema
was demonstrated at histopathologic analysis in early autopsy
studies of smokers dying from emphysema (6). A highprevalence of current or former smokers is noted in a series
of IPF patients, varying from 41% to 83% (23).
In a multicenter case-control study, a history of smoking
was associated with an increased risk of developing IPF, with
an odds ratio of 1.6 (24). In a recent meta-analysis of observa-
tional studies examining environmental and occupational risk
factors for IPF, statistically signiﬁcant increased risk for IPF
was associated with cigarette smoking and exposures (25).
The overall odds ratio for smoking as a risk factor for IPF
was 1.58. There is an independent strong association between
smoking and the development of familial interstitial pneumo-
nia of various subtypes including UIP (odds ratio, 3.6; 95%
conﬁdence interval, 1.3–9.8) (26).
Recent work suggests that smoking may have a detrimental
effect on IPF survival, with survival and severity-adjusted sur-
vival being higher in nonsmokers than in former smokers or in
a combined group of former and current smokers (27).
IPF is the most common form of idiopathic ILD, manifest-
ing in the 6th–7th decades with a slight male predominance
(28). The wide range in this estimate is probably explained
by the lack of uniform deﬁnition used in identifying cases of
IPF as well as differences in study designs and populations.
Clinical features include gradually progressing dyspnea,
chronic cough, and bibasilar inspiratory crackles (28). Digital
clubbing is seen in approximately two-thirds of the patients.
PFTs usually demonstrate a restrictive defect with reduced
lung volumes and diffusing capacity (7).
The typical chest radiograph in IPF shows bilateral basal
and peripheral reticular opacities. Progressive ﬁbrosis leads
to a reduction in lung volumes and honeycombing. Typical
high-resolution CT features allowing conﬁdent diagnosis are
irregular reticular opacities, traction bronchiectasis, and hon-
eycombing in a basal peripheral and subpleural distribution.
In particular, honeycombing is a core ﬁnding in UIP that usu-
ally facilitates distinction from other types of chronic IIPs at
high-resolution CT (7).
It should be noted that in patients with pre-existing emphy-
sema, the lung volumes and ﬂow rates may be normal due to
the counteracting physiological effects of emphysema and
ﬁbrosis (29). In such patients with coexisting emphysema and
IPF, pulmonary function testing may only reveal a severely re-
duced diffusing capacity. HRCT will verify the coexistence of
these two processes in the lung (22).
The association between pulmonary ﬁbrosis and lung
cancer risk has been debated (30). Hubbard et al. (31) recently
described a population-based cohort study in which the
incidence of lung cancer was increased in patients with IPF,
independent of the effect of cigarette smoking. On balance,
however, the evidence is conﬂicting regarding this point and
additional studies are needed (30).3. Results
In 25 patients (n= 25, 62.5%) (age range 32–61 years, mean
age 47 years ± 5) HRCT showed predominantly upper lobar
hyperinﬂation with centrilobular nodules and peribronchial
thickening, 16 of whom had also upper lobar faint ground
glass opacities and 9 of whom had associated upper lobar cen-
trilobular emphysema. Blood gases were slightly impaired in
all patients. All patients had mild restrictive pulmonary
function changes; three of the patients with centilobular
346 Y.Y. Sabri, M.F. Faridemphysema had associated mild obstructive PFT changes.
HRCT, PFT and clinical ﬁndings all suggested RB-ILD.
BAL was done in 19 patients and showed macrophages with
brownish content.
Five patients (n= 5, 12.5%), (32–82 years-old, mean age
63 year ± 4) had bilateral lower lobar ground glass opaciﬁca-
tion; three of them had small cysts in HRCT. There was upper
lobar centrilobular emphysema in all of the ﬁve patients. Bi-
basal crepitation was heard on auscultation. The patients
had ﬁrst degree upper limb clubbing. Mixed PFT changes of
obstructive and restrictive types were found. Blood gases were
impaired. Both bronchoalveolar lavage ﬂuid and lung biopsy
specimen showed increased proportion of dusty brown alveo-
lar macrophages together with minimal ﬁbrosis in all subjects.
The HRCT, PFT, clinical, BAL and biopsy results were all
diagnostic of early DIP changes.
Three patients (n= 3, 7.5%) (55–65 years, mean age
57 year ± 2) HRCT showed bilateral predominantly lower lo-
bar ground glass opacities, sub pleural prominent interlobular
septae with traction bronchiectasis and traction bronchiolecta-
sis, associated with multiple variable-sized cysts. All those pa-
tients had associated upper lobar changes of centrilobular
emphysema. All of the patients had upper limbs clubbing
(one with ﬁrst degree and two with second degree). All had
bi-basal crepitation on auscultation. All had mixed PFT
changes of obstructive and restrictive types. Blood gases were
impaired. Both bronchoalveolar lavage ﬂuid and lung biopsy
specimen showed increased proportion of dusty brown alveo-
lar macrophages together with ﬁbrosis. The HRCT, PFT, clin-
ical, BAL and biopsy results were all diagnostic of advanced
DIP changes.
In six patients (n= 6, 15%) (32–66 years, mean age
54 year ± 6) HRCT showed bilateral predominantly lower lo-
bar sub pleural prominent interlobular septae with traction
bronchiectasis and traction bronchiolectasis and areas of hon-
eycombing. All those patients had associated upper lobar
changes of centrilobular emphysema. All of the patients had
ﬁrst-to-second degree upper limbs clubbing. All had bi-basal
crepitation on auscultation. All had mixed PFT changes of
obstructive and restrictive types. Blood gases were impaired.Table 2 Summary of the HRCT ﬁndings.
Number of cases HRCT ﬁndings
25 25/25 (100%): Bilateral predominantly upper loba
16/25 (64%): upper lobar faint ground glass opac
9/25 (36%): associated upper lobar centrilobular e
5 5/5 (100%)Bilateral lower lobar subpleural ground
3/5 (60%) small cysts in HRCT
5/5 (100%) upper lobar centrilobular emphysema
3 3/3 (100%): bilateral predominantly lower lobar g
prominent interlobular septae with traction bronc
associated with multiple cysts
3/3 (100%): associated upper lobar centrilobular e
6 6/6 (100%): bilateral predominantly lower lobar s
with traction bronchiectasis, traction bronchiolect
6/6(100%): associated upper lobar changes of cen
1 Marked hyperinﬂation of both lung ﬁelds with to
by variable sized bizarre shaped cystsTrans-bronchial lung biopsy was done in all patients showing
usual interstitial pneumonia (UIP) changes with ﬁbrosis and
areas of honeycombing.
One patient (30 year-old) showed marked hyperinﬂation of
both lung ﬁelds with total substitution of normal lung paren-
chyma by variable sized bizarre shaped cysts. The patient
had second-to-third degree clubbing of both upper limbs.
Markedly impaired pulmonary function with mixed obstruc-
tive and restrictive type changes were seen. Blood gases were
markedly impaired. The HRCT ﬁndings together with the clin-
ical and laboratory results; all favoured the diagnosis of
PLCH.
Summary of the HRCT ﬁndings are presented in Table 2.
4. Discussion
Cigarette smoking is a recognized risk factor for the develop-
ment of interstitial lung disease (ILD). There is strong evidence
supporting a causal role for cigarette smoking in the develop-
ment of respiratory bronchiolitis ILD (RB-ILD), desquama-
tive interstitial pneumonitis (DIP), and pulmonary
Langerhans cell histiocytosis (PLCH). In addition, former
and current smokers may be at increased risk for developing
idiopathic pulmonary ﬁbrosis (IPF). The combination of lower
lung ﬁbrosis and upper lung emphysema is being increasingly
recognized as a distinct clinical entity in smokers. High-resolu-
tion computed tomography is sensitive for the detection and
characterization of ILD and may allow recognition and classi-
ﬁcation of the smoking-related ILDs (SR-ILDs) into distinct
individual entities (7).
High resolution CT is the imaging modality of choice in pa-
tients with suspected emphysema or smoking-related intersti-
tial lung disease (33).
Our study was planned to recognise the different interstitial
lung diseases related to cigarette smoking with the ratio of
each pathology, the incidence and the ability of HRCT to
properly diagnose different lesions effectively.
According to the literature, RB-ILD usually affects current
smokers 30–40 years of age. There is a slight male predomi-
nance. Mild cough and dyspnea are the most commonHRCT diagnosis
r centrilobular nodules RB-ILD
ities
mphysema
glass opaciﬁcation EARLY DIP
round glass opaciﬁcation subpleural
hiectasis and traction bronchiolectasis,
ADVANCED DIP
mphysema
ubpleural prominent interlobular septae
asis and areas of honeycombing
UIP
trilobular emphysema
tal substitution of normal lung parenchyma PLCH
Fig. 2 RB-ILD in a 42-year-old male smoker with progressive
dyspnea and restrictive PFT results. Sagittal reconstructed high-
resolution CT image shows evident hyperinﬂated right upper lobe
with ground glass opaciﬁcation and centrilobular nodules.
HRCT ﬁndings in smokers 347presenting symptoms. Inspiratory crackles are present in one-
half of patients, and digital clubbing is rare (23). PFT results
may be normal or show a mixed obstructive-restrictive pattern.
In HRCT, respiratory bronchiolitis-associated interstitial lung
disease often manifests with centrilobular ground-glass nod-
ules, thickening of central and peripheral airways with associ-
ated centrilobular emphysema and air trapping on HRCT.
These ﬁndings appear predominantly in the upper lobes
(10,31). According to Attili et al. (7), the most common
high-resolution CT ﬁndings in RB-ILD are centrilobular nod-
ules, ground-glass opacities, and thickening of the bronchial
walls, which predominate in the upper lobes. Upper lobe
emphysema is also commonly present. A small percentage of
patients have a reticular pattern due to ﬁbrosis in the absence
of honeycombing and traction bronchiectasis (7). Our 25
smoker patients diagnosed as RB-ILD had an age range of
32–61 years (mean age 47 years ± 5). Their main presenting
symptom was progressive dyspnea. General and chest examin-
ations revealed no signiﬁcant abnormality. Blood gases were
slightly impaired in all patients. All patients had mild restric-
tive pulmonary function changes; three of the patients only
with centilobular emphysema had associated mild obstructive
PFT changes. HRCT showed hyperinﬂated upper lobes with
typical changes of predominantly upper lobar centrilobular
nodules (Fig. 1) and peribronchial thickening, sixteen
patients had also upper lobar faint ground glass opacities
(Figs. 2 and 3) and only nine had associated upper lobar
centrilobular emphysema (Fig. 5). None of our cases showed
traction bronchiectasis or bronchiolectasis. Also, none of our
patients had ﬁbrosis or reticulation.
Although the term desquamative interstitial pneumonitis
has been retained in the consensus classiﬁcation of IIPs, it is
considered a misnomer, as the predominant pathologic feature
is the intraalveolar accumulation of pigmented macrophages
and not desquamation of epithelial cells as previously thought.
The condition represents the end spectrum of RB-ILD with
similar pathologic ﬁndings and an almost invariable associa-
tion with smoking. DIP affects cigarette smokers in their 4th
or 5th decades. Males are affected nearly twice as often as
females. Dyspnea and dry cough are the most commonFig. 1 RB-ILD in a 48-year-old male smoker who presented
with dyspnea and restrictive PFT results. High-resolution CT
image obtained through the upper lungs shows bilateral hyperin-
ﬂation and centrilobular nodules.
Fig. 3 DIP in a 73-year old male patient, presented with dyspnea
and mixed PFT results. High-resolution CT image obtained
through the lower lungs shows bilateral sub-pleural ground glass
opacity.presenting symptoms, and the onset is usually insidious. Inspi-
ratory crackles are heard in 60% of patients, and digital club-
bing occurs in nearly one-half of patients. The most common
and striking PFT abnormality is marked reduction in diffusing
capacity, with reductions of 50% or more being common.
Restrictive defects are also common. Patients with advanced
disease may have hypoxemia at rest or with exertion.
The predominant abnormality at high-resolution CT in pa-
tients with DIP is ground-glass opacity, which may be periph-
eral, patchy, or diffuse in distribution. A peripheral sub pleural
and basal predominance of ground-glass opacity is most com-
monly seen. Honeycombing is uncommon. Coexistent emphy-
sema may be present (32,7). Koyama et al. (35) and Lynch
et al. (36)stated that the abnormality has a lower-zone and
Fig. 4 DIP in a 55-year-old male smoker who presented with dyspnea and mixed PFT results. High-resolution CT images (a), (b) axial
images, (c) sagittal reconstructed image and coronal reconstructed image; show bilateral sub-pleural predominantly lower lobar ground
glass opacity with prominent intralobular interstitium seen as reticulation. Multiple bilateral variable-sized cysts recognized. Upper lobes
show signs of centilobular emphysema.
348 Y.Y. Sabri, M.F. Faridperipheral distribution in the majority of cases. Irregular linear
opacities and a reticular pattern are frequent but are limited in
extent and are usually conﬁned to the lung bases. Honeycom-
bing is uncommon, but well-deﬁned cysts may occur within the
areas of ground-glass opaciﬁcation. The cysts are usually
round, thin-walled, and less than 2 cm in diameter. The
ground-glass opaciﬁcation usually regresses with treatment.
Progression of ground-glass opaciﬁcation to a reticular pattern
occurs infrequently (<20% of cases) (34,35).
Our study involved eight patients with HRCT changes
suggestive of DIP. All patients were males, age range 32–82
years-old. All of the patients had upper limb clubbing, bi-basal
crepitation on auscultation, mixed PFT changes of obstructive
and restrictive types and impaired blood gases. Both broncho-
alveolar lavage ﬂuid and lung biopsy specimen that were taken
showed increased proportion of dusty brown alveolar macro-
phages together with ﬁbrosis. HRCT showed bilateral predom-
inantly lower lobar ground glass opacities in all of the eight
patients (Figs. 3 and 4). This was associated with multiple
variable-sized cysts in six patients (75% of DIP patients). In
three patients (37.5% of DIP patients) the size of the cysts
was more than the assumed 2 cm cysts mentioned in thelecture. Three patients (37.5% of the cases) showed sub pleural
prominent interlobular septae with traction bronchiectasis and
traction bronchiolectasis. All of the eight patients had associ-
ated upper lobar changes of centrilobular emphysema. None
of the patient showed honeycombing.
Epidemiologic studies have suggested that there is some
relationship between smoking and idiopathic pulmonary ﬁbro-
sis, the clinical entity associated with the pathologic diagnosis
of usual interstitial pneumonia (UIP), this association is less
strong than for PLCH, DIP, and RB-ILD (3,23). IPF is the
most common form of idiopathic ILD, manifesting in the
6th–7th decade with a slight male predominance. Clinical fea-
tures include gradually progressing dyspnea, chronic cough,
and bibasilar Inspiratory crackles. Digital clubbing is seen in
approximately two-thirds of patients. PFTs usually demon-
strate a restrictive defect (28,7). High-resolution CT ﬁndings
consist of honeycombing, traction bronchiectasis and intralob-
ular interstitial thickening with sub pleural and lower lung pre-
dominance (6).
Six of our patients; diagnosed as UIP, had ﬁrst-to-second
degree upper limb clubbing. All had bi-basal crepitation on
auscultation. All had mixed PFT changes of obstructive and
Fig. 5 UIP in a 60-year-old male smoker who presented with dyspnea and mixed PFT results. High-resolution CT images; axial image
(a), and sagittal reconstructed image (b); show bilateral subpleural predominantly lower lobar ground glass opacity with prominent
intralobular interstitium seen as reticulation, with traction bronchiectasis and bronchiolectasis. Left lower lobar honeycombing was seen.
Upper lobes show signs of centilobular emphysema.
Fig. 6 PLCH in a 28-year-old male smoker who presented with
marked dyspnea and restrictive PFT results. High-resolution, CT
image in sagittal (a), and coronal (b) reconstructed images showed
marked hyperinﬂation of both lung ﬁelds with total substitution of
normal lung parenchyma by variable sized bizarre shaped cysts.
Fig. 7 PLCH in a 30-year-old male smoker who presented with
marked dyspnea and restrictive PFT results. High-resolution, CT
image in sagittal (a), and coronal (b) reconstructed images showed
mild hyperinﬂation of both lung ﬁelds with total substitution of
normal lung parenchyma by variable sized bizarre shaped cysts.
HRCT ﬁndings in smokers 349restrictive types. Blood gases were impaired. HRCT showed
bilateral predominantly lower lobar sub pleural prominent
interlobular septae with traction bronchiectasis and traction
bronchiolectasis and areas of honeycombing (Fig. 5). All those
patients had associated upper lobar changes of centrilobular
emphysema.
Adult pulmonary Langerhans’ cell histiocytosis (Figs. 6 and
7) is a rare disorder of unknown etiology that occurs predom-
inantly in young smokers, with an incidence peak at 20–
40 years of age. In adults, pulmonary involvement with Lan-
gerhans’ cell histiocytosis usually occurs as a single-system dis-
ease and is characterized by focal Langerhans’ cell granulomas
inﬁltrating and destroying distal bronchioles.High-resolution computed tomography (HRCT) of the
chest is essential to the diagnosis, typically showing a combina-
tion of nodules, cavitated nodules, and thick- and thin-walled
cysts (36).
In this study only one patient (28 year-old) was diagnosed
as PLCH. HRCT showed marked hyperinﬂation of both lung
ﬁelds with total substitution of normal lung parenchyma by
variable sized bizarre shaped cysts (Fig. 6). The patient had
second-to-third degree clubbing of both upper limbs, markedly
impaired pulmonary function with mixed obstructive and
restrictive types changes, and blood gases were markedly im-
paired. The HRCT ﬁndings together with the clinical and lab-
oratory results; all favoured the diagnosis of PLCH.
Twenty-three patients in this study had upper lobar emphy-
sema in addition to the SR-ILD. Nine had associated RB-ILD
350 Y.Y. Sabri, M.F. Farid(Fig. 2), eight had DIP (Fig. 4), and six had associated UIP
(Fig. 5). Cottin and colleagues (38)have described this as a
‘‘syndrome’’ of combined emphysema and ﬁbrosis. Their study
involved 61 patients; all smokers, with a mean age of 65 years.
Dyspnoea on exertion was present in all patients. Basal crack-
les were found in 87% and ﬁnger clubbing in 43%. All had
PFT changes (37). They named the syndrome ‘combined pul-
monary ﬁbrosis and emphysema (CPFE)’. The combination
of emphysema in the upper lobes and ﬁbrosis in the lower
lobes (CPFE) is being increasingly recognized as a distinct en-
tity in smokers (37,38). Patients are almost exclusively men in
their 6th and 7th decades. Lung volumes are relatively pre-
served despite markedly impaired diffusion capacity and hyp-
oxemia during exercise. Honeycombing, reticular opacities,
and traction bronchiectasis are the most frequent ﬁndings at
high-resolution CT in the lower lungs, while the upper lungs
exhibit paraseptal and centrilobular emphysema (7). In some
cases of CPFE, emphysema and ﬁbrosis may co-occur in the
same area of the lung (37). There is a high prevalence of pul-
monary hypertension in CPFE, and this is a critical determi-
nant of prognosis. Median survival is reported to be
6.1 years, better than in patients with IPF alone but worse than
expected for emphysema in the absence of ﬁbrosis. None of
our cases however had pulmonary hypertension.
5. Conclusion
In the appropriate clinical evaluation, and in the presence of
typical ﬁndings, high-resolution CT plays an essential role in
evaluation and deﬁnite diagnosis of SR-ILD, and this may
obviate further testing. However, lung biopsy may be needed
when the ﬁndings at high-resolution CT are relatively nonspe-
ciﬁc or when a conﬁdent deﬁnitive diagnosis is needed.
We can conclude from this study that HRCT is highly rec-
ommended for diagnosing and follow up of smoking related
interstitial lung disease and is considered to be the best diag-
nostic modality.
Conﬂict of interest
None.
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